T-Cell Prolymphocytic Leukemia: An Overview of Current and Future Approaches.
alemtuzumab
bcl2
cytogenetic profile
hdac inhibitor
jak-stat
mtcp1
refractory
relapsed
t-cell prolymphocytic leukemia
tcl1
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
09 Feb 2021
09 Feb 2021
Historique:
entrez:
17
3
2021
pubmed:
18
3
2021
medline:
18
3
2021
Statut:
epublish
Résumé
T-cell prolymphocytic leukemia (T-PLL) is a rare mature T-cell hematologic neoplasm with a very poor prognosis and limited treatment options to date. Single-agent alemtuzumab remains the first line of therapy for the treatment-naive and relapsed/refractory patients. Prospective clinical trials are difficult to conduct given that these patients have a short life expectancy after the initial diagnosis. As a result, researchers are implementing the use of targeted therapies in vitro and ex vivo followed by in vivo trials on a small subset of patients which are reviewed here. Newer approaches in the treatment of T-PLL are developing based on recognizing the cytogenetic phenotype of each patient and targeting the identified defective genes that are usually involved in the cell cycle regulation such as protooncogenes, tumor suppressors, and deoxyribonucleic acid (DNA) repair genes. These could potentially redirect the management in the near future and improve the overall survival (OS) and the progression-free survival (PFS) for these patients.
Identifiants
pubmed: 33728186
doi: 10.7759/cureus.13237
pmc: PMC7948687
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e13237Informations de copyright
Copyright © 2021, Colon Ramos et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Cancers (Basel). 2019 Nov 21;11(12):
pubmed: 31766351
Biol Blood Marrow Transplant. 2010 Apr;16(4):543-7
pubmed: 19961946
Clin Cancer Res. 2019 Dec 15;25(24):7331-7339
pubmed: 31471312
Blood. 2001 Sep 15;98(6):1721-6
pubmed: 11535503
Br J Haematol. 2010 Jun;149(6):907-10
pubmed: 20201944
Blood Cancer J. 2018 Jan 19;8(1):11
pubmed: 29352181
Am J Transl Res. 2011 Feb;3(2):166-79
pubmed: 21416059
Blood. 2011 Nov 24;118(22):5799-802
pubmed: 21948296
J Hematol Oncol. 2019 Apr 11;12(1):38
pubmed: 30975222
Cancers (Basel). 2019 Feb 19;11(2):
pubmed: 30791487
Leuk Lymphoma. 2019 Jul;60(7):1626-1631
pubmed: 30997845
Med Sci Monit. 2007 Apr;13(4):RA69-80
pubmed: 17392661
Leuk Lymphoma. 2020 Feb;61(2):445-449
pubmed: 31566032
Leuk Lymphoma. 2016;57(4):942-4
pubmed: 26292711
Blood. 2014 Aug 28;124(9):1460-72
pubmed: 24825865
Blood. 1983 Oct;62(4):873-82
pubmed: 6349718
Leukemia. 2018 Mar;32(3):774-787
pubmed: 28804127
Cold Spring Harb Perspect Biol. 2013 Feb 01;5(2):
pubmed: 23378584
Br J Haematol. 1998 Nov;103(2):488-94
pubmed: 9827924
Immunol Res. 2014 Aug;59(1-3):203-10
pubmed: 24906530
Cold Spring Harb Perspect Biol. 2012 Mar 01;4(3):
pubmed: 22383755
Blood. 2017 Dec 7;130(23):2499-2503
pubmed: 28972014
Leukemia. 2012 May;26(5):972-6
pubmed: 22116553
Biomed Pharmacother. 2020 Jun;126:110107
pubmed: 32247279
Blood. 1991 Dec 15;78(12):3269-74
pubmed: 1742486
Oncotarget. 2017 Nov 1;8(61):104664-104686
pubmed: 29262669
Br J Haematol. 2015 Mar;168(6):916-9
pubmed: 25316212
J Clin Oncol. 2009 Nov 10;27(32):5425-30
pubmed: 19805674
Blood. 2019 Oct 3;134(14):1132-1143
pubmed: 31292114
Ther Adv Hematol. 2020 Oct 13;11:2040620720933761
pubmed: 33117517
Leuk Res. 2018 Apr;67:1-5
pubmed: 29407180
Curr Hematol Malig Rep. 2020 Apr;15(2):113-124
pubmed: 32034661
Sci Transl Med. 2015 Jun 24;7(293):293ra102
pubmed: 26109102
Cancer. 2013 Jun 15;119(12):2258-67
pubmed: 23512246
Bone Marrow Transplant. 2019 Sep;54(9):1391-1398
pubmed: 30664723
Ann Oncol. 2017 Jul 1;28(7):1554-1559
pubmed: 28379307